R&D Systems Inc. Tocris Bioscience Boston Biochem

RS 102895 hydrochloride

Cat. No. 2089

RS 102895 hydrochloride C21H21F3N2O2.HCl [1173022-16-6]

Price and Availability

For RS 102895 hydrochloride pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 1'-[2-[4-(Trifluoromethyl)phenyl]ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one hydrochloride

Biological Activity

CCR2-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 μM respectively. Also inhibits α1A, α1D and 5-HT1A receptors.

Technical Data

M.Wt:
426.86
Formula:
C21H21F3N2O2.HCl
Solubility:
Soluble to 75 mM in DMSO
Purity:
>99 %
Storage:
Desiccate at RT
CAS No:
1173022-16-6

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

References

Clark et al (1983) Synthesis and antihypertensive activity of 4'-substituted spiro[4H-3,1-benzoxazine-4,4'piperidin]-2(1H)-ones. J.Med.Chem. 26 657. PMID: 6842505.

Mirzadegan et al (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J.Biol.Chem. 275 25562. PMID: 10770925.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Keywords: RS 102895 hydrochloride, supplier, CCR2b, chemokine, receptor, antagonists, Chemokine, Receptors, RS102895, hydrochloride

Quick Order

Find multiple products by catalog number

divider line

Immunology Guide

Immunology Research Guide

Highlights over 150 products for immunology research. Request a copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

New Product Guide

NPG

Highlights 140 new products added in the first half of 2014. Request a copy or view PDF today.

divider line

New Products in this Area

DC 260126

FFA1 (GPR40) antagonist

AR-C 118925XX

Selective, competitive P2Y2 receptor antagonist

NIBR 189

Potent and selective EBI2 (GPR183) receptor antagonist

ONO AE3 208

High affinity and selective EP4 antagonist

TCS 3035

GPR35 agonist

PF 5274857 hydrochloride

Potent and selective Smoothened (Smo) receptor antagonist

GSK 137647

Potent and selective FFA4 (GPR120) agonist

AH 7614

Selective FFA4 (GPR120) antagonist

Sign-up for new product e-alerts
divider line

Bio-Techne Events

One Day Symposium

Bio-Techne Symposium 2015

Autophagy in Inflammatory Diseases and Cancer

March 17, 2015

Paris, France